Brought to you by 
CAT, Human Genome Sciences in $67mm antibody collaboration
20 May 2002
Executive Summary
In exchange for use of Cambridge Antibody Technology's fully human antibodies and antibody technology, Human Genome Sciences will pay (uf)$54.9mm up front, which gives them a 6% stake in the company, purchasing 1.67mm CAT shares at about $33 (UK20.75) each (a (pr)20% premium to market price). In addition, HGS will pay (uf)$12mm up front in licensing and three years worth of research support, plus milestones and sales royalties.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CAT, Human Genome Sciences in $67mm antibody collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice